Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

September 30, 2008

Conditions

Degenerative Arthritis

Interventions

BIOLOGICAL

TissueGene-C(Low dose)

3.0 x 10\^6 cells

BIOLOGICAL

TissueGene-C(Medium dose)

1.0 x 10\^7 cells

BIOLOGICAL

TissueGene-C(High dose)

3.0 x 10\^7 cells

Trial Locations (1)

Samsung Medical Center, Seoul